The Glasgow 2024 conference included several important sessions on ART, including upcoming pipeline drugs and the issues of drug resistance with integrase inhibitors.
José Arribas, from La Paz Hospital, Madrid, presented an update on a wealth of drugs in development that have extended dosing options from oral weekly combinations to a range of compounds given by injection or infusion every 2, 3, 4 or 6 months.
The great potency of many new compounds and stronger resistance profiles mean that many combinations only involve two drugs. Nine studies at Glasgow included new data on these compounds.
One caution is that these combinations are nucleoside-sparing and therefore without HBV coverage.
Read the full report by Simon Collins, HIV i-Base here.
All HIV i-Base reports from HIV Glasgow 2024 can be accessed here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.